Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injecti... Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Show more
- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting...
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (βRani Therapeuticsβ or βRaniβ) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 9.84848484848 | 1.32 | 1.51 | 1.31 | 215833 | 1.41992701 | CS |
4 | 0.08 | 5.83941605839 | 1.37 | 1.61 | 1.24 | 338583 | 1.40011293 | CS |
12 | -0.88 | -37.7682403433 | 2.33 | 2.67 | 1.24 | 478851 | 1.84318746 | CS |
26 | -1.64 | -53.074433657 | 3.09 | 3.75 | 1.24 | 1008326 | 2.60879434 | CS |
52 | -2.24 | -60.7046070461 | 3.69 | 8.75 | 1.24 | 558674 | 2.85893228 | CS |
156 | -16.65 | -91.9889502762 | 18.1 | 27.13 | 1.24 | 223347 | 3.53401903 | CS |
260 | -9.81 | -87.1225577265 | 11.26 | 36.27 | 1.24 | 216907 | 5.38602158 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.